GlassScriptPhysician profile
Michaela M Breski
NPI 1528407939
$1,287.90
in general payments reported to CMS, 2019-2025
15 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $396 · 2023: $395 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.84 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $477.43 | 2021-2025 | |
| Janssen Biotech, INC. | $217.10 | 2022-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.62 | 2022-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $83.46 | 2022-2023 | Entyvio |
| Ardelyx, INC. | $77.85 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $67.17 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $45.08 | 2021 | |
| Intercept Pharmaceuticals, INC. | $40.14 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $33.21 | 2022-2023 | Sutab |
| Aimmune Therapeutics, INC. | $32.80 | 2025 | Vowst |
| Gilead Sciences, INC. | $24.58 | 2025 | |
| Medtronic, INC. | $19.04 | 2023 | Interstim |
| Phathom Pharmaceuticals, INC. | $17.31 | 2025 | Voquezna |
| Albireo Pharma, INC. | $15.70 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.41 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Breski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.